Introduction
============

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia \[[@R1]\], \[[@R2]\]. 5--10% of the over 60 years old and up to 15% of the 80 years old have AF. In about 30% of patients AF is asymptomatic \[[@R3]\]. AF is associated with a 5-fold increased risk of thromboembolic stroke and a 1.5-fold increased risk of fatal stroke \[[@R4]\], \[[@R5]\]. Oral anticoagulation (OAC) with vitamin K antagonists (VKA, e.g. phenprocoumon, warfarin) significantly reduces stroke risk by up to 68% \[[@R6]\]. Although OAC increases bleeding risk, it provides an overall benefit and was shown to be cost-effective \[[@R7]\], \[[@R8]\]. OAC is recommended by guidelines for patients with moderate to high risk of stroke and no contraindications. Additionally, the use of direct oral anticoagulants (DOACs) is increasing quickly, although there is still a lack of experience with long-term treatment \[[@R9]\], \[[@R10]\], \[[@R11]\], \[[@R12]\]. Antiplatelet agents are recommended for patients at low risk of stroke based on CHA~2~DS~2~-VASc score or with contraindications against OAC \[[@R11]\], \[[@R12]\].

An effective treatment with VKA requires INR (international normalised ratio) monitoring and an adjustment of the treatment regimen. Rate and rhythm management are further important aspects of AF treatment \[[@R4]\], \[[@R5]\].

International analyses and one German study using health claims data frequently show high rates of up to 50% of AF patients without OAC \[[@R13]\], \[[@R14]\], \[[@R15]\], \[[@R16]\], \[[@R17]\]. Physician related factors affecting OAC prescription have been investigated, but are difficult to assess using health claims data \[[@R18]\].

The aim of this study was to determine the quality of care in AF patients in primary care with focus on OAC treatment, reasons for non-prescription of OAC and rhythm-control treatment. In a second step we compared assessment of OAC rates based on data from practice records with health claims data.

Materials and methods
=====================

Study design and sample
-----------------------

This is a cross-sectional study based on clinical and claims-data from 29 general practitioners (GP). This sample was recruited by contacting all GPs (N=182) in the region Vorpommern-Greifswald. The mean age of the participating GPs was 51 years (SD 7), 62% were men and mean years practising was 15 years. Characteristics of participants corresponded to the average in Mecklenburg-Vorpommern (MV). The study was approved by the local Ethics Committee.

Measurements
------------

### Clinical data

Study patients were identified using electronic medical records (EMR). All patients with at least one documented International Classification of Diseases (ICD-10) code I48.- between 07/2011--06/2012 were eligible for study inclusion. Patients seen as vacation coverage, with private health insurance and patients who died during the study period were excluded. Definite AF was defined if documented as a diagnosis in a hospital discharge letter or on ECG. Patients with documented successful cardioversion or catheter ablation were defined to have AF. Patients without hospital diagnosed AF and no AF on ECG were excluded from the study.

Pseudonymised data on age, sex, demographics, medication, INR-testing and co-morbidities for each patient were extracted by medical staff from the EMR and/or paper records using a standardized case report form. Anonymised copies of the most recent hospital discharge letters, ECG- and medication plan were obtained if available. Missing data was completed in an interview with the GP.

### Claims data

Pseudonymised claims data used for billing was obtained from the regional association of statutory health insurance physicians (Kassenärztliche Vereinigung Mecklenburg-Vorpommern).

All patients with at least one ICD-code I48.- between 07/2011--06/2012 were eligible for the study. We excluded patients seen as vacation coverage and patients who died during the study period. For each patient, all diagnoses and procedures coded in ambulatory care were available.

A patient was defined to be on OAC, if one of the fee schedule items 32026 (prothrombin time), 32113 (plasma prothrombin time), 32114 (capillary blood prothrombin time), 32015 (oral anticoagulant therapy) or alternatively the ICD-10-GM-code Z92.1 (personal history of long-term (current) use of anticoagulants) was coded at least once in the study period. The schedule items were used as a proxy of an OAC treatment with a vitamin K antagonist.

Data analysis
-------------

We calculated crude and adjusted OAC treatment rates based on clinical and claims data. Crude OAC rates were defined as:
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For claims data, only a calculation of treatment rates for VKA could be performed. Adjusted treatment rates were calculated based on clinical data according to guideline recommendations \[[@R4]\], \[[@R5]\]. OAC contraindications were defined based on bleeding risk (HAS-BLED score) and additional predefined criteria (Table 1 [(Tab. 1)](#T1){ref-type="fig"}) \[[@R4]\], \[[@R5]\], \[[@R19]\], \[[@R20]\]. Intermittent contraindications for OAC (e.g. invasive procedures) were disregarded. We calculated adjusted OAC rates subtracting patients without OAC treatment but with a justified reason for non-prescription of OAC or patients with an alternative antithrombotic therapy according to the ESC guideline from the denominator \[[@R4]\], \[[@R5]\]:
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To calculate adjusted treatment rates for the claims data, we estimated individual stroke and bleeding risk using a modified CHA~2~DS~2~-VASc and HAS-BLED score adapted from Wilke et al. \[13\] (Table 2 [(Tab. 2)](#T2){ref-type="fig"}). Patients with a CHA~2~DS~2~-VASc score ≤1 or HAS-BLED score ≥3 were subtracted from the denominator.

We calculated pooled and practice-specific crude and adjusted OAC rates and corresponding confidence intervals. Calculations were performed using SAS 9.3, SAS Institute Inc., Cary, NC, USA.

Results
=======

Study population
----------------

We included 927 patients from 29 primary care practices (mean age 75 years, SD 10, 54% men) based on EMR and 1,247 patients (mean age 75 years, SD 10, 52% men) based on claims data in the study (Table 3 [(Tab. 3)](#T3){ref-type="fig"}). The mean number of included patients per GP practice was 36 (SD 20, median 28) based on EMR and 48 (SD 33, median 43) based on claims data. 7% of the patients lived in a nursing home.

Main comorbidities included hypertension, vascular disease, diabetes mellitus and heart failure (Table 3 [(Tab. 3)](#T3){ref-type="fig"}).

Indication for OAC and risk of bleeding
---------------------------------------

The mean CHA~2~DS~2~-VASc score was 3.5 (SD 1.5) based on EMR and 3.9 (SD 1.7) based on claims data (Table 3 [(Tab. 3)](#T3){ref-type="fig"}). 93% (860/927) of patients based on EMR and 91% (1130/1247) of patients based on claims data had an OAC indication (Table 3 [(Tab. 3)](#T3){ref-type="fig"}).

The mean HAS-BLED score was 2.5 (SD 1.0) based on EMR and 1.0 (SD 0.6) based on claims data. An increased bleeding risk (HAS-BLED score ≥3) was found in 47% based on practice data and in 2% based on claims data.

Based on EMR, 69% (640/927) were treated with phenprocoumon, 5% (46/927) with a DOAC and 32% (294/927) with an antiplatelet agent or heparin. The crude OAC treatment rate was 69% (95% CI 65.0%--72.0%) (Figure 1 [(Fig. 1)](#F1){ref-type="fig"}), corresponding to a crude OAC treatment rate of 71% (SD 17) per GP practice (Table 4, Figure 2 [(Fig. 2)](#F2){ref-type="fig"}).

After correcting for diagnosis of a definite AF defined by the study criteria, guideline based OAC indication, bleeding risk, individual contraindications and alternative antithrombotic treatment, the adjusted mean OAC treatment rate was 90% (95% CI 87.4%--91.6%) (Figure 1 [(Fig. 1)](#F1){ref-type="fig"}). The average adjusted OAC treatment rate was 91% (95% CI 87.4%--94.1%) per GP practice (Table 4, Figure 2 [(Fig. 2)](#F2){ref-type="fig"}).

Based on claims data, the crude total OAC treatment rate was 61% (95% CI 58.3%--63.8%) (Figure 1 [(Fig. 1)](#F1){ref-type="fig"}) and the average crude OAC treatment rate was 66% (SD 15) per GP practice. After taking into account a guideline based indication for OAC, individual contraindications and alternative antithrombotic treatment, 63% (95% CI 59.9%--65.6%) of patients received an OAC based on claims data (Figure 1 [(Fig. 1)](#F1){ref-type="fig"}). This corresponds to an average OAC treatment rate of 67% (SD=15) per GP practice (Table 4 [(Tab. 4)](#T4){ref-type="fig"}, Figure 2 [(Fig. 2)](#F2){ref-type="fig"}).

Reasons for OAC underuse
------------------------

The most common reasons for OAC underuse were increased risk of falling (23%, 67/287), dementia (19%, 54/287) and an increased risk of bleeding (15%, 43/287). Further reasons included tumors, social aspects, mental disorders, dialysis and history of cardioversion (2%, 6/287) or catheter ablation (2%, 7/287) as well as rare diseases affecting haemostasis.

Rhythm and frequency control therapy
------------------------------------

Based on EMR, 82% (758/927) of AF patients received at least one medication for rate control and 12% (110/927) at least one medication for rhythm control. Medications prescribed for rate control included betablockers (69%, 641/927), digitoxin (34%, 316/927), verapamil (3%, 25/927) and the I~f~-blocker ivabradine (0.1%, 1/927). Prescribed rhythm-control medications included amiodarone (5%, 43/927), dronedarone (3%, 23/927) or flecainide (4%, 40/927).

Discussion
==========

Main findings
-------------

The present study assesses quality of care for AF patients in primary care. This is the first study in Germany to compare data from medical records with claims data in this patient group. Based on our analysis, a proportion of 90% of AF patients in primary care received a guideline concordant anticoagulation treatment after adjusting for reasons for non-prescription. Using claims data to calculate OAC rates underestimated the true proportion of correctly treated AF patients by 30%. 82% of AF patients received medication for rate control and 12% medication for rhythm control.

Strengths and limitations
-------------------------

This is to our knowledge the first study in Germany comparing OAC based on clinical data with claims data. The response rate of 16% is comparable to other primary care studies \[[@R21]\], \[[@R22]\]. Characteristics of the participating practices corresponded well to the average in MV. It is probable, that GPs with interest in the topic were more likely to participate.

Patient characteristics corresponded well between practice and claims data. To minimize bias due to coding errors, AF diagnosis and comorbidities were evaluated using an interview with the GP and paper records. Data on comorbidities, obtained from the treating GP might be subject to observer bias.

Lower patient numbers and level of comorbidities identified in the claims data, suggest undercoding of AF in our study. To minimize bias due to undercoding, we applied a wider range of ICD codes to define comorbidities (Table 2 [(Tab. 2)](#T2){ref-type="fig"}) \[[@R13]\]. Since we had no access to prescription data we could not adjust crude OAC rates based on claims data for alternative medications. Despite these limitations our results allow for the definition of a reference value regarding the proportion of OAC in AF patients based on clinical and claims data.

OAC treatment
-------------

Three German studies using clinical data assessed OAC treatment rates. An OAC rate of 83% and a guideline concordant antithrombotic treatment rate of 93% were reported from the prospective German clinical registry ATRIUM \[[@R23]\]. An OAC treatment rate of 88% was found in a study comprising 361 AF patients from 45 primary care practices \[[@R24]\]. However, INR was estimated to be in the target range in only 56% of the treatment time. The study did not investigate alternative antithrombotic treatments. In contrast, a large prospective population based study reported a considerably lower OAC rate of 57% for antithrombotic therapy in 161 AF patients \[[@R25]\]. Only 5% (46/927) of AF patients in our study were treated with a DOAC. The expected rise in treatment rates poses a need to employ more detailed treatment data in future analyses. This data was not available in the claims data analysed for our study.

OAC treatment indication and bleeding risk
------------------------------------------

In our study, more than 90% of AF patients were eligible for OAC based on a CHA~2~DS~2~-VASc score. The suitability of the CHA~2~DS~2~-VASc score for assessment of stroke risk and OAC indication has been controversially discussed and a recent Swedish study suggests overtreatment for low CHA~2~DS~2~-VASc score values \[[@R26]\], \[[@R27]\], \[[@R28]\], \[[@R29]\], \[[@R30]\].

47% (440/927) of AF patients in our study had an increased bleeding risk based on EMR, but only 15% based on the assessment of the treating physician. Several patient characteristics disfavouring OAC use (e.g. dementia) constitute an area of uncertainty with a need for individual shared decision making.

In our study, 2% (7/287) of patients did not receive an OAC after successful cardioversion or catheter ablation. Due to the high rate of recurrent AF and the lack of evidence of reduction in long term stroke risk, a continuation of OAC is now recommended \[[@R31]\], \[[@R32]\], \[[@R33]\], \[[@R34]\].

Rate and rhythm control
-----------------------

The proportion of AF patients with rate control medication is a potential quality indicator. 18% (169/927) of AF patients in our study did not receive any medication for rate control, 69% (641/927) were treated with a beta blocker and 3% (25/927) with verapamil. However, beta blockers are recommended by guidelines as first line treatment, especially in patients with heart failure \[[@R5]\], \[[@R35]\]. Despite the narrow therapeutic range and lack of evidence for effects on relevant clinical outcomes, 34% (316/922) of AF patients were treated with digitalis glycosides. We hypothesise that patients received digitalis for a long period and treatment was not adapted to current recommendations \[[@R36]\]. One patient in our study was treated with ivabradine, although it is not licensed for AF treatment \[[@R37]\].

In our study, amiodarone (5%, 43/927), flecainide (4%, 40/927) or dronedarone (2/927 3%) were used for rhythm control. However, rhythm control has no clinical benefits compared to rate control in AF patients \[[@R34]\]. Amiodarone and dronedarone have relevant adverse effects, are not indicated in permanent AF and should be discontinued \[[@R4]\], \[[@R5]\]. A good effectiveness of flecainide was demonstrated for maintaining sinus rhythm after cardioversion especially in young patients without structural heart disease \[[@R38]\]. However, it is likely that in the majority of patients on long-term flecainide treatment (98%, 39/40) in our study, a re-evaluation is necessary because of known proarrhythmic effects.

OAC is currently recommended for AF patients with rate control medication and in patients under treatment with rhythm control medication and no stable sinus rhythm for at least 12 weeks \[[@R35]\], \[[@R37]\]. This was still controversially discussed at the time of the study.

Comparison with claims data
---------------------------

A German study based on claims data of 183,448 AF patients, estimated that only 28% to 33% patient days were covered by OAC \[[@R13]\]. Prevalence rates for OAC or antithrombotic treatment were not reported. Our analysis shows that crude OAC rates based on claims data used for billing underestimate the true guideline adherence. This was mainly due to individual contraindications, which could not be documented using ICD codes. We estimate that an OAC rate of 70% based on EMR and 65% based on claims data corresponds to a very good adherence. An analysis strategy similar to the one employed in our study could be used for benchmarking purposes if applied to a representative sample (e.g. federal state level) and to develop a feedback instrument for individual practices. Full treatment information is currently only available in statutory health insurance data. Due to the high number of statutory health insurance funds (\>50) and limited access to this data feedback at the individual practice level is therefore currently impossible.

Conclusion
==========

High rates of patients with AF receive a guideline concordant drug therapy. There is a considerable difference between crude and adjusted OAC treatment rates using EMR and claims data. This is mainly due to individual contraindications and uncoded comorbidities in EMR and claims data. Therefore, quality assessment based on crude claims data leads to an underestimation of the quality of care. According to our results, an OAC treatment rate of 60% to 70% based on claims data from the regional association of statutory health insurance physicians would be an appropriate target range for a quality indicator representing a satisfactory quality of care in a single practice. Our data indicates that drugs for rhythm control which so far have rarely been subject of quality measurements should be part of quality improvement activities. Readily available claims data could be used for feedback on practice level to improve quality of care.

Notes
=====
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